Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

16.61USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$16.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,645,877
52-wk High
$18.29
52-wk Low
$3.55

Select another date:

Thu, Nov 3 2016

BRIEF-Exelixis announces Q3 and YTD 2016 financial results

* Exelixis announces third quarter and year to date 2016 financial results and provides corporate update

BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib

* Cabozantinib met primary endpoint of improving progression-free survival as compared to Sunitinib

BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib

* Ipsen and its partner Exelixis announce positive results from Phase 2 CABOSUN Trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

BRIEF-Exelixis elects Julie Anne Smith to board

* Exelixis elects Julie Anne Smith to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Exelixis announces redemption of remaining 4.25 convertible senior subordinated notes

* Exelixis announces redemption of all remaining 4.25% convertible senior subordinated notes due 2019

BRIEF-Exelixis Q2 loss per share $0.16

* Exelixis announces second quarter and year to date 2016 financial results and provides corporate update

BRIEF-Ipsen and Exelixis receive positive CHMP opinion for Cabometyx

* Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx (cabozantinib) for treatment of advanced renal cell carcinoma in adults

Select another date: